CEBPB and neoplasm: From the four new variants, only c.-137C > A was validated through Sanger sequencing in the tumor and constitutive DNA in heterozygous state (Fig. 2); the PROMO software predicted that this transversion creates novel binding sites for transcription factors (NFI/CTF and C/EBPbeta).